A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers
- 6 August 2013
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 69 (12) , 1997-1999
Abstract
A four-drug cytochrome P450 (CYP) phenotyping cocktail was developed to rapidly and safely determine CYP2D6, CYP2C19, CYP2C9 and CYP1A2 enzyme activity and phenotype. The cocktail consisted of the single CYP phenotyping probes of 50 mg tramadol (CYP2D6), 20 mg omeprazole (CYP2C19), 25 mg losartan (CYP2C9) and 200 mg caffeine (CYP1A2) and was administered as a single oral dose. For enzyme activity measurements, urine was collected as 8 h post-administration and blood was sampled at 4 h. The enzyme activity was determined by metabolic ratios of molar concentrations of the drugs and their enzyme catalyzed metabolites and was correlated to the relevant genotypes. In a pilot study in 12 healthy male volunteers the CYP genotype–phenotype correlation and robustness of the cocktail was successfully determined without detection of any adverse drug reactions. In the subsequent population study, four female volunteers experienced unexpected and unacceptable moderate and severe adverse reactions (ARs) of headache, dizziness, nausea, vomiting, blue fingers, nails and lips and difficulties in urinating, which led to the study being prematurely terminated after inclusion of only 25 subjects (17 males, 7 females). Attention must be paid to adverse reactions when designing new combinations of phenotype cocktails regardless of the doses and drugs involved. We specifically warn against the combination of tramadol, omeprazole, losartan and caffeine.Keywords
This publication has 19 references indexed in Scilit:
- Mechanistic and functional differentiation of tapentadol and tramadolExpert Opinion on Pharmacotherapy, 2012
- Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatmentPsychopharmacology, 2012
- The Hypoalgesic Effect of Oxycodone in Human Experimental Pain Models in Relation to the CYP2D6 Oxidation PolymorphismBasic & Clinical Pharmacology & Toxicology, 2009
- CYP2C9 genetic variants and losartan oxidation in a Turkish populationEuropean Journal of Clinical Pharmacology, 2004
- Enantioselective HPLC method for quantitative determination of tramadol andO-desmethyltramadol in plasma and urine: Application to clinical studiesChromatographia, 2003
- Metabolism of the analgesic drug ULTRAM ® (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolitesXenobiotica, 2002
- Theophylline has no advantages over caffeine as a putative model drug for assessing CYP1A2 activity in humansBritish Journal of Clinical Pharmacology, 1997
- Determination of Urinary Metabolites of Caffeine for the Assessment of Cytochrome P4501A2, Xanthine Oxidase, and N-Acetyltransferase Activity in HumansTherapeutic Drug Monitoring, 1996
- Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlationsPharmacogenetics, 1996
- Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotypePharmacogenetics, 1995